A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus

Trial Profile

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Ocrelizumab (Primary) ; Corticosteroids; Corticosteroids; Cyclophosphamide; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms BELONG
  • Sponsors Genentech
  • Most Recent Events

    • 17 Jun 2017 Results (n=522) assessing the predictive value of early measurements of the level of proteinuria and to identify proteinuria cutoffs that best identify patients who will achieve CRR at 18 months from LUNAR and BELONG trials presented at the 18th Annual Congress of the European League Against Rheumatism
    • 13 Jul 2013 Status changed from active, no longer recruiting to discontinued.
    • 05 Jun 2013 Results published in the Arthritis and Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top